BR112015013463A8 - Derivados de carboxamida indol como antagonistas do receptor de p2x7 - Google Patents
Derivados de carboxamida indol como antagonistas do receptor de p2x7Info
- Publication number
- BR112015013463A8 BR112015013463A8 BR112015013463A BR112015013463A BR112015013463A8 BR 112015013463 A8 BR112015013463 A8 BR 112015013463A8 BR 112015013463 A BR112015013463 A BR 112015013463A BR 112015013463 A BR112015013463 A BR 112015013463A BR 112015013463 A8 BR112015013463 A8 BR 112015013463A8
- Authority
- BR
- Brazil
- Prior art keywords
- indol
- carboxamide derivatives
- receptor antagonists
- derivatives
- carboxamide
- Prior art date
Links
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 title abstract 3
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title abstract 2
- 101710189965 P2X purinoceptor 7 Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12196711 | 2012-12-12 | ||
EP12196711.1 | 2012-12-12 | ||
PCT/IB2013/060794 WO2014091415A1 (en) | 2012-12-12 | 2013-12-11 | Indole carboxamide derivatives as p2x7 receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015013463A2 BR112015013463A2 (pt) | 2017-11-14 |
BR112015013463A8 true BR112015013463A8 (pt) | 2017-12-26 |
BR112015013463B1 BR112015013463B1 (pt) | 2022-06-14 |
Family
ID=47325947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015013463-7A BR112015013463B1 (pt) | 2012-12-12 | 2013-12-11 | Derivados de carboxamida indol como antagonistas do receptor de p2x7 |
Country Status (21)
Country | Link |
---|---|
US (1) | US9718774B2 (pt) |
EP (1) | EP2931717B1 (pt) |
JP (1) | JP6295269B2 (pt) |
KR (1) | KR102232742B1 (pt) |
CN (1) | CN104812749B (pt) |
AR (1) | AR093921A1 (pt) |
AU (1) | AU2013356850B2 (pt) |
BR (1) | BR112015013463B1 (pt) |
CA (1) | CA2890886C (pt) |
CL (1) | CL2015001529A1 (pt) |
EA (1) | EA029644B1 (pt) |
ES (1) | ES2618056T3 (pt) |
IL (1) | IL239295A0 (pt) |
MA (1) | MA38192B1 (pt) |
MX (1) | MX368044B (pt) |
PH (1) | PH12015501339A1 (pt) |
PL (1) | PL2931717T3 (pt) |
SG (1) | SG11201504369SA (pt) |
TW (1) | TWI612034B (pt) |
WO (1) | WO2014091415A1 (pt) |
ZA (1) | ZA201504974B (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2838640C (en) | 2011-07-22 | 2019-06-11 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
EP2804865B1 (en) | 2012-01-20 | 2015-12-23 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as p2x7 receptor antagonists |
EP2935211B1 (en) | 2012-12-18 | 2016-11-09 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as p2x7 receptor antagonists |
KR102220847B1 (ko) | 2013-01-22 | 2021-02-26 | 이도르시아 파마슈티컬스 리미티드 | P2x7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
KR102222220B1 (ko) | 2013-01-22 | 2021-03-03 | 이도르시아 파마슈티컬스 리미티드 | P2x7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
EP2905282A1 (en) | 2014-02-05 | 2015-08-12 | AXXAM S.p.A. | Substituted thiazole or oxazole as P2X7 receptor antagonists |
US10060269B2 (en) | 2015-12-21 | 2018-08-28 | General Electric Company | Cooling circuits for a multi-wall blade |
US10119405B2 (en) | 2015-12-21 | 2018-11-06 | General Electric Company | Cooling circuit for a multi-wall blade |
US10221696B2 (en) | 2016-08-18 | 2019-03-05 | General Electric Company | Cooling circuit for a multi-wall blade |
US10227877B2 (en) | 2016-08-18 | 2019-03-12 | General Electric Company | Cooling circuit for a multi-wall blade |
US10267162B2 (en) | 2016-08-18 | 2019-04-23 | General Electric Company | Platform core feed for a multi-wall blade |
US10208607B2 (en) | 2016-08-18 | 2019-02-19 | General Electric Company | Cooling circuit for a multi-wall blade |
US10208608B2 (en) | 2016-08-18 | 2019-02-19 | General Electric Company | Cooling circuit for a multi-wall blade |
EP3290416A1 (en) * | 2016-08-31 | 2018-03-07 | AXXAM S.p.A. | Substituted n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives and their use as p2x7 receptor antagonist |
US20200172530A1 (en) * | 2017-03-14 | 2020-06-04 | Dana-Farber Cancer Institute, Inc. | Small Molecule Sensitization of BAX Activation for Induction of Cell Death |
CN111072505A (zh) * | 2019-12-27 | 2020-04-28 | 合肥华方医药科技有限公司 | 一种文拉法辛杂质的制备方法 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
PL350907A1 (en) | 1999-04-09 | 2003-02-10 | Astrazeneca Ab | Adamantane derivatives |
SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
WO2004058731A1 (en) | 2002-12-31 | 2004-07-15 | Pfizer Products Inc. | Benzamide inhibitors of the p2x7 receptor |
PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
WO2004099146A1 (en) | 2003-05-12 | 2004-11-18 | Pfizer Products Inc. | Benzamide inhibitors of the p2x7 receptor |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
SE0302139D0 (sv) | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
JP2007535553A (ja) * | 2004-04-29 | 2007-12-06 | アボット・ラボラトリーズ | アミノ−テトラゾール類縁体および使用方法 |
SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
SE0402925D0 (sv) | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
EP1844003A4 (en) | 2005-01-27 | 2010-09-22 | Astrazeneca Ab | NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR |
US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
WO2007055374A1 (ja) | 2005-11-14 | 2007-05-18 | Mitsubishi Tanabe Pharma Corporation | 骨粗鬆症治療剤 |
US20100298285A1 (en) | 2006-03-16 | 2010-11-25 | Kelly Michael G | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof |
CA2645652A1 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
BRPI0709596A2 (pt) | 2006-03-16 | 2011-07-19 | Renovis Inc | compostos bicicloeteroarila como moduladores de p2x7 e seus usos |
WO2007109172A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
WO2007109201A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為p2x7調節劑之雙環雜芳基化合物與其用途 |
GB0611154D0 (en) | 2006-06-06 | 2006-07-19 | Glaxo Group Ltd | Novel receptor antagonists and their methods of use |
WO2007141267A1 (en) | 2006-06-06 | 2007-12-13 | Glaxo Group Limited | N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration |
MX2009000117A (es) | 2006-07-06 | 2009-01-23 | Glaxo Group Ltd | N-fenilmetil-5-oxo-prolin-2-amidas sustituidas como antagonistas de receptores p2x7 y sus metodos de uso. |
EA201300152A1 (ru) | 2006-11-27 | 2013-07-30 | Х. Лундбекк А/С | Гетероариламидные производные |
TW200838516A (en) | 2007-01-31 | 2008-10-01 | Merck & Co Inc | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
ES2576643T3 (es) | 2007-03-09 | 2016-07-08 | Second Genome, Inc. | Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos |
EP2139879B1 (en) | 2007-03-22 | 2012-07-11 | AstraZeneca AB | Quinoline derivatives for the treatment of inflammatory diseases |
GB0705882D0 (en) | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
WO2008116845A1 (en) | 2007-03-28 | 2008-10-02 | Glaxo Group Limited | Piperidinone carboxamide derivatives as p2x7 modulators |
JP2010522710A (ja) | 2007-03-29 | 2010-07-08 | グラクソ グループ リミテッド | P2x7調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体 |
JP2010523524A (ja) | 2007-04-03 | 2010-07-15 | グラクソ グループ リミテッド | P2x7調節因子としてのイミダゾリジンカルボキサミド誘導体 |
JP2010523668A (ja) | 2007-04-10 | 2010-07-15 | ハー・ルンドベック・アクチエゼルスカベット | P2x7拮抗薬としてのヘテロアリールアミド類似体 |
WO2008125600A2 (en) | 2007-04-11 | 2008-10-23 | Glaxo Group Limited | Pyrazole derivatives as p2x7 modulators |
DE602008005582D1 (de) | 2007-05-10 | 2011-04-28 | Glaxo Group Ltd | Pyrazolderivate als p2x7-modulatoren |
WO2009012482A2 (en) | 2007-07-19 | 2009-01-22 | H.Lundbeck A/S | 5-membered heterocyclic amides and related compounds |
NZ582056A (en) * | 2007-08-10 | 2012-08-31 | Lundbeck & Co As H | Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation |
PE20091036A1 (es) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | Derivado de quinolina como antagonista del receptor p2x7 |
WO2009074518A1 (en) | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations of prolinamide p2x7 modulators with further therapeutic agents |
GB0724258D0 (en) | 2007-12-12 | 2008-01-30 | Glaxo Group Ltd | Novel combinations |
GB0724625D0 (en) | 2007-12-18 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
KR20100099178A (ko) | 2007-12-18 | 2010-09-10 | 글락소 그룹 리미티드 | P2x7 조절제로서의 5-옥소-3-피롤리딘카르복스아미드 유도체 |
WO2009108551A2 (en) | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
CA2719745C (en) | 2008-03-25 | 2016-07-05 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
CN102066360B (zh) * | 2008-04-22 | 2013-10-30 | 詹森药业有限公司 | 喹啉或异喹啉取代的p2x7拮抗剂 |
ATE541832T1 (de) | 2009-04-14 | 2012-02-15 | Affectis Pharmaceuticals Ag | Neuartige p2x7r-antagonisten und ihre verwendung |
GB0919594D0 (en) | 2009-11-09 | 2009-12-23 | Glaxo Group Ltd | Compounds |
US20120157494A1 (en) | 2010-12-16 | 2012-06-21 | Harris Iii Ralph New | Isoindolyl compounds |
CN103391923A (zh) | 2011-02-22 | 2013-11-13 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的苯甲酰胺衍生物 |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
CA2838640C (en) | 2011-07-22 | 2019-06-11 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
EP2804865B1 (en) | 2012-01-20 | 2015-12-23 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as p2x7 receptor antagonists |
TWI598325B (zh) | 2012-10-12 | 2017-09-11 | H 朗德貝克公司 | 苯甲醯胺類 |
TW201427947A (zh) | 2012-10-12 | 2014-07-16 | Lundbeck & Co As H | 環狀胺 |
EP2935211B1 (en) | 2012-12-18 | 2016-11-09 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as p2x7 receptor antagonists |
KR102220847B1 (ko) | 2013-01-22 | 2021-02-26 | 이도르시아 파마슈티컬스 리미티드 | P2x7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
KR102222220B1 (ko) | 2013-01-22 | 2021-03-03 | 이도르시아 파마슈티컬스 리미티드 | P2x7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
-
2013
- 2013-12-11 MX MX2015007493A patent/MX368044B/es active IP Right Grant
- 2013-12-11 SG SG11201504369SA patent/SG11201504369SA/en unknown
- 2013-12-11 AR ARP130104631A patent/AR093921A1/es unknown
- 2013-12-11 AU AU2013356850A patent/AU2013356850B2/en not_active Ceased
- 2013-12-11 PL PL13824192T patent/PL2931717T3/pl unknown
- 2013-12-11 MA MA38192A patent/MA38192B1/fr unknown
- 2013-12-11 KR KR1020157018405A patent/KR102232742B1/ko active IP Right Grant
- 2013-12-11 JP JP2015547233A patent/JP6295269B2/ja not_active Expired - Fee Related
- 2013-12-11 US US14/651,922 patent/US9718774B2/en active Active
- 2013-12-11 EP EP13824192.2A patent/EP2931717B1/en active Active
- 2013-12-11 EA EA201500628A patent/EA029644B1/ru not_active IP Right Cessation
- 2013-12-11 TW TW102145695A patent/TWI612034B/zh not_active IP Right Cessation
- 2013-12-11 ES ES13824192.2T patent/ES2618056T3/es active Active
- 2013-12-11 BR BR112015013463-7A patent/BR112015013463B1/pt not_active IP Right Cessation
- 2013-12-11 WO PCT/IB2013/060794 patent/WO2014091415A1/en active Application Filing
- 2013-12-11 CA CA2890886A patent/CA2890886C/en active Active
- 2013-12-11 CN CN201380060692.2A patent/CN104812749B/zh not_active Expired - Fee Related
-
2015
- 2015-06-04 CL CL2015001529A patent/CL2015001529A1/es unknown
- 2015-06-09 IL IL239295A patent/IL239295A0/en unknown
- 2015-06-15 PH PH12015501339A patent/PH12015501339A1/en unknown
- 2015-07-10 ZA ZA2015/04974A patent/ZA201504974B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA38192A1 (fr) | 2017-03-31 |
EP2931717B1 (en) | 2016-12-07 |
CL2015001529A1 (es) | 2015-09-25 |
BR112015013463B1 (pt) | 2022-06-14 |
KR102232742B1 (ko) | 2021-03-26 |
WO2014091415A1 (en) | 2014-06-19 |
AR093921A1 (es) | 2015-06-24 |
SG11201504369SA (en) | 2015-07-30 |
ES2618056T3 (es) | 2017-06-20 |
US9718774B2 (en) | 2017-08-01 |
IL239295A0 (en) | 2015-07-30 |
MX368044B (es) | 2019-09-17 |
MA38192B1 (fr) | 2017-11-30 |
KR20150093229A (ko) | 2015-08-17 |
AU2013356850B2 (en) | 2018-02-01 |
PL2931717T3 (pl) | 2017-05-31 |
CA2890886A1 (en) | 2014-06-19 |
JP6295269B2 (ja) | 2018-03-14 |
CN104812749B (zh) | 2016-12-14 |
EP2931717A1 (en) | 2015-10-21 |
PH12015501339A1 (en) | 2015-09-02 |
ZA201504974B (en) | 2017-11-29 |
TWI612034B (zh) | 2018-01-21 |
BR112015013463A2 (pt) | 2017-11-14 |
CA2890886C (en) | 2020-10-27 |
JP2016508967A (ja) | 2016-03-24 |
CN104812749A (zh) | 2015-07-29 |
AU2013356850A1 (en) | 2015-07-30 |
MX2015007493A (es) | 2015-09-04 |
TW201427944A (zh) | 2014-07-16 |
US20150322008A1 (en) | 2015-11-12 |
EA029644B1 (ru) | 2018-04-30 |
EA201500628A1 (ru) | 2015-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015013463A8 (pt) | Derivados de carboxamida indol como antagonistas do receptor de p2x7 | |
BR112016002459A8 (pt) | Derivados de benzimidazolil-metil ureia como agonistas receptores de alx | |
UA111640C2 (uk) | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 | |
MY165584A (en) | Ampk-activating heterocyclic compounds and methods for using the same | |
BR112014017735A2 (pt) | derivados de amida heterocíclicos como antagonistas do receptor de p2x7 | |
CR20150424A (es) | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno | |
TR201810944T4 (tr) | Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri. | |
PH12014502540B1 (en) | Benzimidazole-proline derivatives | |
TR201900662T4 (tr) | Cb2 reseptör antagonistleri olarak triazolo[4,5-d]pirimidin türevleri. | |
EA201591748A1 (ru) | Модуляторы p2x7 | |
CR20140311A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
EA201590931A1 (ru) | Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций | |
UY34350A (es) | Derivados de pirazolquinolinona, su preparación y su uso terapéutico. | |
BR112015023161A8 (pt) | derivados de piridin-4-ila | |
BR112015027394A2 (pt) | derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2 | |
BR112019001551A2 (pt) | moduladores do receptor de piperidina cxcr7 | |
UY35653A (es) | Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
EA201501163A1 (ru) | Модуляторы рецептора cxcr7 | |
ECSP13013016A (es) | Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf | |
BR112016001238A8 (pt) | Derivados de 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona, seus usos e composição farmacêutica os compreendendo | |
BR112013017923A8 (pt) | Derivados de 2-metóxi-piridin-4-il | |
EA201590886A1 (ru) | Замещенные производные индола | |
UA112586C2 (uk) | Похідні бензімідазолпроліну |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
B25C | Requirement related to requested transfer of rights |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/12/2013, OBSERVADAS AS CONDICOES LEGAIS |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2752 DE 03-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |